摘要
目的:探讨非奈利酮及氨体舒通治疗慢性心力衰竭(CHF)的临床价值.方法:将2021年1月2021年12月南方医科大学南方医院白云分院心血管内科收治的200例CHF患者随机均分为对照组(n=100)和实验组(n=100),分别使用氨体舒通和非奈利酮治疗.比较两组临床疗效、左室舒张末径(LVEDD)、左室射血分数(LVEF)、6分钟步行试验(6MWT)、N末端B型利钠肽原(NT-proBNP)、心源性死亡率、心衰再入院率、高血钾发生率、肌酐清除率<30％发生率、不良反应发生情况.结果:实验组总有效率明显高于对照组(98.0％vs 91.0％,P<0.05).与治疗前及对照组治疗后比较,实验组治疗后LVEF、6MWT均明显增高,NT-proBNP、LVEDD水平均明显降低(P均<0.05).实验组不良反应总发生率与对照组无明显差异(9.0％vs 7.0％,P>0.05).两组心源性死亡率无明显差异(P>0.05);实验组心衰再入院率、高血钾发生率、肌酐清除率<30％发生率均明显低于对照组(P均<0.05).结论:与氨体舒通比较,非奈利酮治疗CHF疗效更好,心功能改善程度更佳,可降低心衰再入院率、高血钾发生率、肌酐清除率<30％发生率.
Abstract
Objective:To explore the clinical value of fenelidone and spironolactone in the treatment of chronic heart failure(CHF).Methods:200 patients with CHF admitted to the hospital from Jan,2021 to Dec,2021 were ran-domly divided into control group(n=100)and experimental group(n=100).The control group used aminoshutong,and the experimental group used fenelidone.The clinical efficacy,left ventricular end diastolic diameter(LVEDD),left ven-tricular ejection fraction(LVEF),6-minute walking test(6MWT),N-terminal pro-natriuretic peptide(NT-proBNP),cardiogenic mortality,readmission rate of heart failure,hyperkalemia,creatinine clearance rate less than 30％and ad-verse reactions were compared between the two groups.Results:The total effective rate in the experimental group was sig-nificantly higher than that in the control group(98.0％vs 91.0％,P<0.05).Compared with before treatment and after treatment in the control group,LVEF and 6MWT in the experimental group increased significantly,while the levels of NT-proBNP and LVEDD decreased significantly(all P<0.05).The total incidence of adverse reactions in the experimental group was no significant difference in the control group(9.0％vs 7.0％,P>0.05).There was no significant difference in cardiogenic mortality between the two groups(P>0.05).Compared with the control group,the readmission rate of heart failure,the incidence of hyperkalemia and the incidence of creatinine clearance rate<30％in the experimental group were significantly reduced(P<0.05).Conclusion:Compared with spironolactone,fenelidone is more effective in the treatment of patients with CHF,and the improvement of cardiac function is better.It can reduce the readmission rate of heart failure,the incidence of hyperkalemia and the incidence of creatinine clearance rate<30％.
维普
万方数据